New analysis from Mangold
Date: 2022-10-13
Mangold sees the case for Alzinova's ALZ-101 candidate strengthened considerably. In an updated analysis, Mangold sees advantages in Alzinova's candidate, which is being developed as a vaccine with a long-acting effect. Mangold raises target price to SEK 9.00 (5.40).